Switzerland

AI Citation Summary

• Country: Switzerland
• Product line: Medical devices
• Regulator / source: Regulatory maturity: High. Swissmedic is a well-established, professional regulatory body. Although Switzerland is not an EU member state, its regulatory framework has long been closely aligned with EU MDR/IVDR. The Swiss Authorized Representative (CH-REP) requirement and the evolving status of the Mutual Recognition Agreement (MRA) are the primary points of attention.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Registration Timelines
• Key fees: Population: Approximately 8.8 million; GDP per capita among the highest globally (~USD 90,000); healthcare expenditure approximately 12% of GDP
• Local requirement: Regulatory maturity: High. Swissmedic is a well-established, professional regulatory body. Although Switzerland is not an EU member state, its regulatory framework has long been closely aligned with EU MDR/IVDR. The Swiss Authorized Representative (CH-REP) requirement and the evolving status of the Mutual Recognition Agreement (MRA) are the primary points of attention.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 8.8 million; GDP per capita among the highest globally (~USD 90,000); healthcare expenditure approximately 12% of GDP
• Healthcare system: Mandatory basic health insurance (LaMal/KVG, Loi sur l'assurance-maladie) covers all residents; a multi-pillar insurance system (basic insurance + supplementary insurance); public and private hospitals coexist; generous medical technology procurement budgets and high receptiveness to advanced devices
• Market characteristics: Medical device market size approximately USD 3–3.5 billion (Switzerland is itself a significant manufacturer and exporter, with a well-developed Medtech industry); strong demand for high-end, innovative products; relatively high pricing freedom; many global Medtech multinationals (Stryker, Abbott, BD, etc.) have their European headquarters in Switzerland; small but high-value market with a reasonable cost-to-entry ratio
• Regulatory maturity: High. Swissmedic is a well-established, professional regulatory body. Although Switzerland is not an EU member state, its regulatory framework has long been closely aligned with EU MDR/IVDR. The Swiss Authorized Representative (CH-REP) requirement and the evolving status of the Mutual Recognition Agreement (MRA) are the primary points of attention.

Market-Entry Logic

Switzerland medical-device entry should be separated into Swissmedic / MedDO / IvDO with CH-REP requirements regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	Swissmedic / MedDO / IvDO with CH-REP requirements	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	FOPH / BAG, SL list, cantonal hospitals and mandatory health insurance	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	Sonova, Straumann, Ypsomed, Hamilton Medical, Roche Diagnostics, Medtronic, Johnson & Johnson MedTech and cantonal hospital buyers	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: EU alignment gaps, CH-REP, high-value hospital procurement, premium pricing scrutiny and strong domestic life-science ecosystem are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Competent Authority: Swissmedic (Swiss Agency for Therapeutic Products, Schweizerisches Heilmittelinstitut / Institut suisse des produits thérapeutiques)
• Official portal: https://www.swissmedic.ch
• Medical Device Database (DMID): https://www.swissmedic.ch/swissmedic/de/home/medizinprodukte.html
• Key regulations:
  • Medical Devices Ordinance (MedDV, Medizinprodukteverordnung / OMéd, Ordonnance sur les dispositifs médicaux), SR 812.213, in force from 26 May 2021, closely aligned with EU MDR 2017/745
  • In Vitro Diagnostics Ordinance (IvDV, In-vitro-Diagnostika-Verordnung), aligned with EU IVDR 2017/746
  • Therapeutic Products Act (HMG, Heilmittelgesetz / LPTh, Loi sur les produits thérapeutiques), SR 812.21, the overarching legislation
  • Switzerland–EU Mutual Recognition Agreement (MRA), Annex 1 (Medical Devices chapter) — currently in a partially suspended state (see special note below)

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Notes
Klasse I / Classe I	Low risk	EU MDR Class I / FDA Class I	General devices; sterile/measuring Class I requires NB involvement
Klasse IIa / Classe IIa	Medium-low risk	EU MDR Class IIa / FDA Class II	NB involvement required
Klasse IIb / Classe IIb	Medium-high risk	EU MDR Class IIb / FDA Class II	More rigorous technical documentation review
Klasse III / Classe III	High risk	EU MDR Class III / FDA Class III	Implants and high-risk active devices

Classification rules fully adopt the EU MDR Annex VIII rules (Rules 1–22) with no local deviations. IVDs are classified per EU IVDR Annex VIII (Class A/B/C/D).

Registration Pathway

Pathway for Foreign Manufacturers

Critical MRA Note:
The Medical Devices chapter of the Switzerland–EU Mutual Recognition Agreement has been "frozen" since 2021 (due to the political breakdown of bilateral negotiations, which prevented the MRA from being updated to cover the EU MDR framework). In practical terms, this means that CE-certified products entering Switzerland can no longer rely on EU NB certificates for a simplified "notification-only" process — manufacturers must now separately notify/register with Swissmedic through the CH-REP procedure, even if a valid CE marking is held. This is the most important operational change since 2021.

1. Confirm EU MDR/IVDR compliance

   • The Swiss MedDV/IvDV framework is closely aligned with EU MDR/IVDR
   • A valid CE marking (issued by an EU-recognized Notified Body) is the core document for Swiss notification
   • Swissmedic generally accepts EU NB certificates as the basis for compliance

2. Appoint a Swiss Authorized Representative (CH-REP)

   • Foreign manufacturers (including those in EU member states) selling devices in Switzerland must mandatorily appoint a CH-REP
   • The CH-REP must be a legal entity registered in Switzerland (or, in specific circumstances, a natural person)
   • The CH-REP must be registered in the Swissmedic EUDAMED-CH system
   • The CH-REP bears the manufacturer's legal responsibility within Switzerland (equivalent to the EU AR role under EU MDR, transposed for Switzerland)

3. Prepare the Swiss Declaration of Conformity (Swiss DoC / Konformitätserklärung)

   • The manufacturer must sign a Swiss Declaration of Conformity that complies with MedDV/IvDV requirements (based on the EU DoC format but must reference Swiss regulatory provisions)
   • Technical Documentation must be essentially equivalent to the EU MDR application file

4. Notification/submission to Swissmedic

   • Class I (including sterile/measuring): A notification (Meldepflicht) must be submitted to Swissmedic together with CH-REP information and the DoC. Swissmedic operates a notification-based system for Class I; no approval is required
   • Class IIa/IIb/III: A formal submission (Konformitätsbewertungsverfahren) must be made to Swissmedic with complete technical documentation and the NB certificate; Swissmedic conducts an independent review, focusing primarily on the CE certificate and the Declaration of Conformity
   • Swissmedic may request the full technical documentation and conduct an independent assessment

5. Labeling and language compliance

   • Product labeling must include CH-REP information (name and address)
   • Labels must be in one or more of Switzerland's four official languages (German/French/Italian/Romansh); in practice, German, French, and Italian are most commonly required
   • If the product already carries EU multi-language labeling (including DE/FR/IT), this generally satisfies Swiss requirements, but CH-REP information must be added

6. Customs clearance and market placement

   • Cleared through customs on the basis of a valid Swissmedic notification/approval
   • Products must carry labeling compliant with MedDV requirements

Key Prerequisites

• Valid CE marking (under the EU MDR/IVDR framework; NB certificate must be current)
• CH-REP appointed and registered with Swissmedic
• Swiss Declaration of Conformity (referencing MedDV/IvDV provisions)
• Labeling includes CH-REP information (in German/French/Italian)
• Swissmedic notification/submission completed

Registration Dossier Requirements

• ISO 13485 certificate (current; certificates from IAF member bodies are accepted)
• Certificate of Free Sale (CFS) (for non-EU manufacturers; typically replaced by CE marking + NB certificate)
• EU NB certificate (Class IIa/IIb/III; must be current)
• EU Declaration of Conformity (EU DoC) (a separate Swiss DoC referencing MedDV provisions must also be signed)
• Device description and intended purpose (in one of DE/FR/IT)
• Summary of Safety and Clinical Performance (SSCP) (Class III and implants)
• Risk management file (ISO 14971; summary acceptable)
• Clinical Evaluation Report (CER) (mandatory for Class IIa and above; must comply with EU MDR requirements)
• IFU and labeling (including CH-REP information; DE/FR/IT versions)
• CH-REP authorization letter and Swiss registration confirmation
• Swissmedic notification confirmation (Class I) or submission form (Class IIa+)

Registration Timelines

Stage	Official Timeframe	Practical Reference
CH-REP appointment and Swissmedic registration	—	2–4 weeks (faster if CH-REP already has a Swissmedic account)
Class I notification (Meldepflicht)	Effective immediately	1–4 weeks (including document preparation)
Class IIa submission	No fixed timeframe	2–4 months
Class IIb submission	No fixed timeframe	3–6 months
Class III submission	No fixed timeframe	4–8 months
Additional Swissmedic technical review (if required)	—	Additional 1–3 months

Practical note: Swiss registration is generally much faster than the EU MDR process, since Swissmedic primarily relies on the work already done by EU Notified Bodies. If EU CE registration has been completed, Swiss registration can typically be accomplished within 3–6 months (Class IIb/III). Swissmedic occasionally requires more in-depth technical review for specific product categories (especially novel devices), which will extend the timeline.

Registration Costs

Item	Estimated Cost (USD)
Swissmedic application fee (Class I notification)	~500–1,500 (CHF 500–1,500)
Swissmedic application fee (Class IIa)	~3,000–6,000
Swissmedic application fee (Class IIb/III)	~6,000–15,000
CH-REP annual fee	3,000–12,000/year (depending on number of products and complexity)
Labeling update cost (adding CH-REP information)	1,000–5,000 (depending on number of products)
Regulatory consultant fee	2,000–8,000
Total budget reference (Class IIb, single device)	~15,000–40,000 (first registration)

Note: Swiss fees are denominated in Swiss Francs (CHF); approximate USD conversion at ~1:1.1 (CHF/USD). Compared to the full EU MDR submission, the incremental cost of a separate Swiss registration is relatively manageable.

Local Agent / Marketing Authorization Holder Requirements

• Local agent mandatory: Yes. All manufacturers registered outside Switzerland — including those in EU member states — must mandatorily appoint a CH-REP.
• Representative qualifications:
  • The CH-REP must be a legal entity registered in the Swiss Commercial Register (Handelsregister) (or, in specific circumstances, a qualified natural person)
  • Must be registered in Swissmedic's "economic operator" database
  • Responsible for ensuring the product's compliance in the Swiss market and for regulatory liaison with Swissmedic
  • No specialized license is required, but the CH-REP must have medical device regulatory knowledge
• Marketing authorization holder rules:
  • Switzerland does not issue a document equivalent to a "registration certificate." Notifications/submissions are made in the manufacturer's name; the CH-REP serves as the Swiss legal contact
  • Changing the CH-REP requires a variation notification to Swissmedic and a labeling update
  • Practical recommendation: Many companies consolidate the EU AR (under MDR Article 11) and the CH-REP roles with a single regulatory affairs firm to reduce management overhead

Import Requirements

• Import permit: Switzerland has no separate medical device import permit system; customs clearance is based on Swissmedic notification/submission documents and the valid CE marking
• Customs requirements:
  • Swiss Customs (Eidgenössische Zollverwaltung / EZV) requires compliance documents
  • Most medical devices benefit from zero or low tariffs (Switzerland has concluded free trade agreements with most major trading partners)
  • VAT (Mehrwertsteuer) applies: standard rate 8.1%; certain medical devices qualify for the reduced rate of 2.6%, depending on classification
• Labeling language: German, French, and Italian (the three de facto official languages); English may be included as a supplement but cannot replace official language labeling; labels must include CH-REP information (name and address)

Post-Market Surveillance

• Adverse event reporting (Vorkommnis-Meldung / Vigilance):
  • Serious adverse events must be reported to Swissmedic within 15 business days
  • Immediately life-threatening events must be reported urgently within 2–3 business days
  • Reports submitted through the Swissmedic Vigilance online platform
  • Swiss adverse event reporting obligations are aligned with EU MDR requirements
• Recall rules: The manufacturer or CH-REP must promptly implement Field Safety Corrective Actions (FSCA); Swissmedic must be notified and a Field Safety Notice (FSN) issued
• Periodic Safety Update Report (PSUR): Submit to Swissmedic at the same frequency required under EU MDR (synchronized with the NB): every 2 years for Class IIa/IIb; every year for Class III and implantables
• Post-market surveillance: Swissmedic conducts regular market surveillance audits to verify product compliance

Renewal Requirements

• Registration validity: Switzerland does not use a conventional "registration certificate" concept. Notifications/submissions remain valid indefinitely but must be maintained in step with CE certificate and technical documentation updates.
• Renewal timing:
  • Submit an update notification to Swissmedic when the EU NB certificate is renewed
  • Significant product changes (design, intended purpose, etc.) must be notified in advance
  • CH-REP changes must be promptly communicated and labeling updated
• Annual maintenance: Keep manufacturer and CH-REP information in the Swissmedic database accurate; periodically confirm that technical documentation is at the latest version

Special Regulatory Requirements

• UDI:
  • The Swiss MedDV adopts UDI requirements consistent with EU MDR (EUDAMED-CH system)
  • The mandatory implementation timeline is broadly synchronized with EU EUDAMED
  • Products already UDI-registered in the EU must be registered by the CH-REP in EUDAMED-CH as well
• Local testing: Additional local testing is generally not required; test reports from EU/internationally recognized laboratories are accepted
• Special category requirements:
  • Radiation-emitting devices or products containing radioactive substances: Must additionally comply with the Radiological Protection Act (StSG/LRaP); an additional permit from FOPH (Federal Office of Public Health) may be required
  • Combination products containing drug components: May require involvement of Swissmedic's pharmaceutical division
  • Software as a Medical Device (SaMD): Classified under MedDV, typically Class IIa and above; additional software validation documentation required
  • IVDs for genetic testing: Must comply with additional requirements under the Human Genetic Testing Act (GUMG/LAGH)

Market Access Channels

• Public hospital procurement (LaMal reimbursement system): Inclusion in the mandatory health insurance reimbursement list (MiGeL, Mittel- und Gegenstände-Liste) is key to public channel coverage. The MiGeL application process is independent of Swissmedic registration and must be submitted separately to the Federal Office of Public Health (BAG/OFSP). High-value devices may require a Health Technology Assessment (HTA) for economic evaluation.
• Private hospitals/clinics: The primary purchasers of higher-value devices; broad supplementary insurance coverage; procurement decisions are made by department heads/procurement teams; brand influence and KOL relationships are important
• E-commerce/distribution: Consumer-grade medical devices (Class I) are sold through pharmacies, medical device retailers, and e-commerce platforms; B2B devices are sold through local distributors
• Government tenders: Federal and cantonal hospitals have independent procurement processes; large tenders are published through the public procurement platform (simap.ch)

Market Entry Strategy

• Recommended approach:

  • Standard path (with existing EU CE marking): Engage a single firm to serve as both EU AR and CH-REP (many regulatory affairs companies offer this bundled service), handle the EU and Swiss notifications in parallel, and maximize efficiency. The incremental registration cost is relatively modest (primarily the CH-REP annual fee and Swissmedic application fee).
  • Non-EU companies without EU CE marking: Strongly recommended to complete EU MDR certification before entering Switzerland, or proceed in parallel. There is no practical pathway advantage to pursuing Swiss registration alone, as Swissmedic requires CE marking as a prerequisite.
  • High-value innovative devices: Switzerland's high GDP per capita and private hospital premium pricing make market entry ROI attractive. Start the CH-REP appointment process during the EU MDR submission; once the CE certificate is issued, Swiss notification can be completed rapidly.

• Key risks:

  1. MRA freeze impact: The Switzerland–EU MRA Medical Devices chapter is currently suspended; manufacturers can no longer rely on "EU approval automatically covering Switzerland." Placing products on the Swiss market without a CH-REP is non-compliant.
  2. Labeling cost: Multi-language labeling requirements (DE/FR/IT + CH-REP information) add label version management complexity; when batch sizes are small, labeling costs are high. Incorporate Swiss requirements into the EU multi-language label design from the outset.
  3. MiGeL reimbursement pathway: Inclusion in MiGeL is the gateway to the public channel, but the application timeline is long (12–24 months) and pricing negotiations are complex. If the target market is primarily private hospitals, this step can be bypassed.
  4. CH-REP stability: If the CH-REP terminates service, the change must be completed before sales are interrupted to avoid compliance gaps.
  5. EUDAMED-CH lag: The EUDAMED-CH system may lag behind the EU EUDAMED in development progress; monitor Swissmedic announcements regularly.

• Practical tips:

  • Although Switzerland has only 8.8 million residents, per capita healthcare spending is extremely high and profit margins on premium devices are excellent; the entry cost relative to EU is lower, making the ROI well worth evaluating
  • Many global Medtech companies have headquarters or European subsidiaries in Switzerland (Zurich, Basel, Zug) that can serve as CH-REP; this is the lowest-cost option
  • Swissmedic officials are fluent in English; technical regulatory communications are relatively straightforward (unlike some markets where language barriers exist)
  • If attending the Zurich DMEA or Basel-area medical device exhibitions, local KOL relationships can be built efficiently

Leveraging Existing CE / FDA / NMPA Approvals

Quick Reference

Certificate	Acceleration Effect	Primary Mechanism
EU CE (MDR/IVDR)	⭐⭐⭐⭐ (very high document reuse value, but not automatic recognition)	After MRA freeze, CE no longer covers Switzerland automatically; however, Swissmedic bases its review on CE technical documentation — CE holders face approximately 30% of the workload compared to non-CE products
US FDA (510(k)/PMA)	⭐⭐	Technical documentation can support Swissmedic registration but no dedicated fast-track pathway exists
China NMPA	⭐	Swissmedic does not recognize NMPA; data carries almost no direct value

EU CE (MDR/MDD/IVDR)

• Recognition mechanism: Prior to 2021, the Switzerland–EU MRA Medical Devices chapter allowed CE-certified products to enter Switzerland through a simplified procedure. From 2021, the MRA Medical Devices chapter entered a "frozen" state (due to the stalled EU–Switzerland bilateral relationship negotiations, which prevented the MRA from being updated to the EU MDR framework). CE marking no longer automatically covers the Swiss market; manufacturers must separately notify Swissmedic. However, Swissmedic's regulatory framework (MedDV/IvDV, SR 812.213) is almost entirely consistent with EU MDR/IVDR in terms of technical documentation format requirements. Swissmedic has explicitly stated that for products holding a valid CE certificate from an EU Notified Body, the EU technical file can serve as the complete core basis for a Swiss submission; Swissmedic generally accepts EU NB certificates as compliance evidence without requiring a redundant technical review (except in special circumstances). In practice, the workload for Swissmedic registration for CE-certified products is approximately 30% of that for non-CE products, with the additional effort focused on: (1) CH-REP appointment and Swissmedic registration; (2) signing a separate Swiss Declaration of Conformity (Swiss DoC) referencing MedDV provisions; and (3) label adjustments (adding CH-REP information and the required format under SR 812.213).
• Practical effect: The marginal cost for CE-certified products to enter Switzerland is very low and the timeline is significantly shortened. Swissmedic's review of CE technical documentation is primarily a desk review; no independent technical re-assessment is required. For Class I devices, only CH-REP notification and a Swiss DoC are needed; for Class IIa and above, the existence of an NB certificate greatly simplifies Swissmedic's review. Overall, holding a CE certificate is the most effective "accelerator" for entering the Swiss market — even with the MRA frozen, the document reuse value remains very significant.
• Key considerations: Note the legal implications of the MRA freeze — the CE certificate itself has no legal force in Switzerland; products must not be placed on the Swiss market before CH-REP notification is completed. The Swiss DoC must be signed separately and must reference Swiss regulations (MedDV/IvDV); the EU DoC cannot be used as a direct substitute. Labels must include CH-REP information; if the EU label did not reserve space for CH-REP details, additional costs will be incurred.

US FDA (510(k) / De Novo / PMA)

• Recognition mechanism: There is no formal mutual recognition agreement between Swissmedic and FDA; FDA approval cannot trigger any Swissmedic submission simplification. FDA technical documentation (clinical data, risk management reports, design V&V test data) overlaps substantially in content with the technical file requirements under MedDV, and can serve as source material for Swissmedic technical documentation preparation. Specifically: (1) ISO 14971 risk management files (generated through FDA QSR review); (2) biocompatibility test reports (ISO 10993 series, accepted by both FDA and Swissmedic); and (3) clinical data summaries (can serve as clinical evidence inputs for the Swiss conformity assessment).
• Practical effect: Reusing FDA documentation can save some preparation work for the Swissmedic technical file, but since Swissmedic's core requirement remains an EU MDR-format technical file, FDA-format documents require structural reorganization (restructuring chapters per MDR Annex II/III). The overall acceleration effect is limited; the primary value lies in reusing clinical data and test reports rather than simplifying the process.
• Key considerations: FDA 21 CFR 820 QSR must be mapped to ISO 13485 (which Swissmedic mandates); a clear cross-reference must be provided. Swissmedic's clinical evaluation requirements are consistent with EU MDR MEDDEV 2.7/1 Rev.4; FDA clinical data must be reorganized within this framework to be effectively supportive.

China NMPA

• Recognition mechanism: Swissmedic does not recognize NMPA registration certificates; there is no acceleration mechanism in the Swiss regulatory framework based on NMPA approval. The NMPA technical documentation structure differs significantly from EU MDR/Swissmedic MedDV requirements, making direct reuse of limited value.
• Practical effect: Essentially no direct value for a Swissmedic registration application. Chinese post-market data (real-world data, adverse event records) may serve as supplementary safety data, but must be professionally compiled with an applicability statement, and Swissmedic weights such evidence relatively low.
• Key considerations: When submitting a Swissmedic registration, do not cite NMPA approval documents as technical compliance evidence. If Chinese clinical data are to be referenced, an English translation must be provided along with an ICH-GCP compliance statement and an applicability analysis of the Chinese patient population relative to the target use population.

Practical Recommendations

1. Optimal path under MRA freeze: CE-certified companies should position Swiss registration as a "rapid post-CE market extension." Complete CH-REP appointment, Swiss DoC signing, and Swissmedic notification within 3–6 months of CE certificate issuance, gaining access to the high-value Swiss market at minimal marginal cost.
2. Advance CH-REP arrangement: The CH-REP must complete Swissmedic system registration before formal submission. Begin selecting the CH-REP when EU NB review approval is imminent and the CE certificate is about to be issued, to avoid wasted time.
3. Global label design: During the CE label design phase, pre-allocate space for CH-REP information (typically a replaceable label sticker or a separate supplement label) to avoid the need for retooling or extensive label revisions for the Swiss market.
4. MRA restart monitoring: EU–Switzerland bilateral negotiations are ongoing; if the MRA Medical Devices chapter is successfully reactivated (brought within the EU MDR framework), market entry for CE-certified companies into Switzerland will be further simplified. Subscribe to Swissmedic news (https://www.swissmedic.ch) and monitor EU–CH bilateral negotiation developments to plan responsive action in advance.
5. MiGeL reimbursement and CE data: When applying for MiGeL (medical device reimbursement list), health economic data accumulated during CE certification (cost-effectiveness analyses, comparative clinical studies) can be used directly to support the MiGeL assessment. Plan Health Technology Assessment (HTA) evidence in parallel during the CE phase.